Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and tolerability of topical SHP141
applied directly to skin lesions in patients with Stage IA, IB, or IIA Cutaneous T-cell
Lymphoma. This study will also investigate the effect of SHP141 on skin lesions in patients
with Stage IA, IB, or IIA CTCL.
Phase:
Phase 1
Details
Lead Sponsor:
TetraLogic Pharmaceuticals
Collaborators:
PPD The Leukemia and Lymphoma Society Therapeutics, Inc. Veristat, Inc.